Is there tissue penetration after application of topical salicylate formulations? [2]

Lancet

Volumn 350, Issue 9078, 1997, Pages 636-

  Cross, Sheree E ^a   Anderson, Chris ^b   Thompson, Melanie J ^a   Roberts, Michael S ^a  

^a PRINCESS ALEXANDRA HOSPITAL   (Australia)

^b LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; SALICYLIC ACID; SALICYLIC ACID METHYL ESTER; TRIETHANOLAMINE SALICYLATE;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG PENETRATION; DRUG TISSUE LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; LETTER; MICRODIALYSIS; NORMAL HUMAN; PRIORITY JOURNAL; SKIN BLOOD FLOW; TOPICAL DRUG ADMINISTRATION;

EID: 0342275223     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)63324-7     Document Type: Article

References (4)

1. Roberts MS, Favretto WA, Meyer A, et al. Topical bioavailability of methylsalicylate. Aust N Z J Med 1982; 12: 305-06.
2. Anderson C, Anderson T, Boman A, et al. Cutaneous micro dialysis for the measurement in-vivo of the percutaneous absorption of organic solvents. Curr Prob Dermatol 1996; 25: 37-46.
3. Megwa SA, Benson HAE, Roberts MS. Percutaneous absorption of salicylates from, commercially available topical products containing methylsalicylate or salicylate salts in rats. J Pharm Pharmacol 1995; 47: 891-96.
4. Morra P, Bartle WR, Walker SE, et al. Serum concentration of salicylic acid following topically applied salicylate derivatives. Ann Pharmacother 1996; 30: 935-40.